Article Details

AstraZeneca's Imfinzi Phase III trial raises trial design questions - Clinical Trials Arena

Retrieved on: 2023-11-21 16:30:12

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Imfinzi Phase III trial raises trial design questions - Clinical Trials Arena. View article details on HISWAI: https://www.clinicaltrialsarena.com/analyst-comment/astrazeneca-imfinzi-phase-iii-trial/

Excerpt

Astrazeneca's Imfinzi is an immune checkpoint inhibitor (ICI) targeting the programmed cell death 1 ligand 1 (PD-L1).

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up